The city of Jacksonville, Florida, currently has 4 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Ascension Medical Group St. Vincent's Lung Institute, Jacksonville, Florida +1 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/23/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/17/2024
Locations: Ascension St. Vincent's, Jacksonville, Florida +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/23/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Idiopathic Pulmonary Fibrosis